Primary-source record
status: RECRUITING → UNKNOWN
Summit initiates Phase 3 HARMONi-10 of ivonescimab vs durvalumab in unresectable Stage III NSCLC
Summit Receives FDA CRL for Ivonescimab BLA in EGFR-Mutated NSCLC
ivonescimab · NCT07228832 registry update
ivonescimab · NCT07158489 registry update
Summit Therapeutics partners with Lunit to use AI-powered SCOPE IO for ivonescimab TME analysis
Summit Therapeutics to Present Ivonescimab Data Across 10 Abstracts at ESMO 2026
Summit Therapeutics and ECOG-ACRIN Collaborate on Phase II/III EA2251 Trial of Ivonescimab in First-Line BTC
Summit Therapeutics opens Phase II SMT112-216 trial of ivonescimab regimens in 1L advanced ccRCC
ivonescimab · NCT05899608 registry update